Suggested remit: To appraise the clinical and cost effectiveness of durvalumab with tremelimumab within its marketing authorisation for untreated non-small-cell lung cancer with no epidermal growth factor receptor - or anaplastic-lymphoma-kinase -positive mutations.
Following on from information provided to NICE by the company in October 2019, the appraisal of Durvalumab with tremelimumab for untreated non-small-cell lung cancer with no EGFR- or ALK-positive mutations [ID1143] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
- Status:
- Discontinued
- Technology type:
- Medicine
- Decision:
- Prioritised
- Process:
- TA
- ID number:
- 1143
Email enquiries
If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 10 November 2022 | Discontinued. Following on from information provided to NICE by the company in October 2019, the appraisal of Durvalumab with tremelimumab for untreated non-small-cell lung cancer with no EGFR- or ALK-positive mutations [ID1143] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 11 October 2019 | Note added to the project documents |
| 12 April 2019 | Note added to the project documents |
| 24 January 2018 - 21 February 2018 | Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators |
| 26 June 2017 | In progress. Topic referred |
| 21 April 2017 | Referral |
For further information on our processes and methods, please see our CHTE processes and methods manual